
    
      This is a multi-center prospective, observational real-world study, targeting patients with
      B-cell non-Hodgkin's lymphomas. This study is designed to evaluate the efficacy and safety of
      lenalidomide single drug or lenalidomide combined with rituximab (with or without other
      drugs) in the real-world setting.

      This study will mainly focus on the following three cohorts:

      Cohort 1: patients diagnosed with CD20-positive diffuse large B-cell lymphoma; Cohort 2:
      patients diagnosed with CD20-positive follicle lymphoma; Cohort 3: patients on maintenance
      treatment who have achieved complete remission or partial remission after induction therapy.
    
  